SOLU-MEDROL (methylprednisolone sodium succinate) by Pfizer is clinical pharmacology glucocorticoids, naturally occurring and synthetic, are adrenocortical steroids that are readily absorbed from the gastrointestinal tract. First approved in 1959.
Drug data last refreshed 2h ago · AI intelligence enriched 1w ago
SOLU-MEDROL is a potent synthetic glucocorticoid (methylprednisolone sodium succinate) administered via injection for rapid anti-inflammatory and immunosuppressive effects. It is used across multiple organ systems to treat inflammatory and immune-mediated disorders, with onset of action within one hour and near-complete excretion within 12 hours. The drug's mechanism relies on profound metabolic effects and immune modulation rather than salt retention, distinguishing it from earlier corticosteroids.
Product approaching loss of exclusivity with minimal Part D utilization signals mature, stable franchise with reduced commercial team expansion opportunity.
CLINICAL PHARMACOLOGY Glucocorticoids, naturally occurring and synthetic, are adrenocortical steroids that are readily absorbed from the gastrointestinal tract. Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on SOLU-MEDROL at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on SOLU-MEDROL offers stable, defensive career positioning in a mature injectable corticosteroid franchise with deep clinical legacy but limited growth runway. Roles emphasize operational excellence, competitive differentiation, and managed care negotiation rather than product expansion or clinical innovation.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo